

The Hon. Greg Hunt MP

Minister for Health Minister for Sport

MEDIA RELEASE

18 January 2018

More support for Australia's world-class medical researchers

The Turnbull Government is today announcing new grant funding of almost \$12 million to provide further support for Australia's world-class medical researchers.

I am delighted to visit the Murdoch Children's Research Institute to announce support for research that will offer new hope for people living with rare ataxia diseases.

Ataxia is a rare and debilitating disease which affects a person's ability to walk, talk and use fine motor skills. Symptoms include a lack of coordination, slurred speech, difficulty eating and swallowing, eye movement abnormalities, trouble walking, gait abnormalities, tremors and heart problems.

Many people with ataxia may eventually be permanently confined to a wheelchair and in later stages be permanently incapacitated.

As part of the Turnbull Government's Medical Research Future Fund (MRFF), a new \$1.7 million grant will allow researchers at the Murdoch Children's Research Institute and the University of Melbourne to conduct separate trials into the benefits of rehabilitation.

The Murdoch Children's Research Institute will trial the effectiveness of rehabilitation for hereditary ataxias – which no medication is proven to benefit – to help sufferers perform the basic tasks needed to maintain their independence.

For those people with difficulty speaking, the University of Melbourne trial will evaluate whether intensive, home-based speech therapy can improve symptoms.

These two trials are the first to receive support through the MRFF's Lifting Clinical Trials and Registries Capacity (LCTRC) program, which supports researchers trying to find new treatments and cures for rare diseases and cancers.

And in a further boost for ataxia research, Dr Louise Corben from the Murdoch Children's Research Institute will also receive a \$431,000 grant.

This funding will support Dr Corben's study into the use of brain stimulation to improve coordination and function in people with Friedreich ataxia – a disease which often shortens life expectancy due to severe heart diseases.

Dr Corben is one of 21 recipients of 2018 Medical Research Future Fund Next Generation Researchers fellowships which are also being announced today. They will share in \$10 million to further their work across a wide range of research subjects.

Research includes tackling poor outcomes for patients with acute myeloid leukaemia, treating methamphetamine addiction, managing staphylococcal infections and improving treatment for depression.

These fellowships fund Australia's next generation of clinical researchers to ensure the best and brightest minds are supported today to make the breakthroughs of tomorrow.

The grants announced today are a further demonstration of the Turnbull Government's unprecedented commitment to health and medical research.

(ENDS)

Next Generation Researchers fellowships:

Researcher/	Project/
Institute/	Summary (from researcher)
Funding	
Professor Elizabeth Elliott	Improving health outcomes for disadvantaged children
University of Sydney	I am a paediatrician researcher dedicated to improving health and quality of life for ill and disadvantaged children. The focus of my Fellowship will be research in three areas: rare childhood diseases, fetal alcohol spectrum disorder, and vaccine-preventable disease, with attention to diagnosis, treatment and prevention. Alignment of my research
\$577,188	and clinical work and my experience in evidence-based medicine will facilitate adoption of my research into clinical care and health policy.
Professor Christopher Levi	Discovery to therapy implementation in acute stroke
The University of Newcastle	Advances in acute stroke therapies are occurring rapidly but challenges remain in their safe and effective delivery to stroke sufferers. This research focuses on testing a potentially superior 'clot busting' drug therapy for acute stroke and on identifying
\$577,188	reasons why one of the most widely used current therapies carries a risk of significant harm due to bleeding into the brain. The work also investigates how to better implement the newest form of acute therapy, mechanical blood clot extraction.
Professor Y C Gary Lee	Translational Research on Malignant Pleural Effusion and Pleural Infection
University of Western Australia	I am a leading researcher in pleural effusions (fluid build-up in the chest) from cancer and infection. I run a multicentre clinical trial team to answer important questions directly relevant to patient care, as well as a lab research group with proven record of
\$481,155	discovery new treatment targets. This fellowship will capitalize on platforms I have built and determine best approach to remove effusions, understand etiologic roles of the fluid ultimately to find ways to stop fluid from forming.
Professor Jacqueline Center	Improving outcomes in osteoporosis and bone health
The Garvan Institute of Medical Research	Osteoporotic fractures are a common and increasing problem as the population ages. They are associated with increased risk of re-fracture and early death yet most patients remain untreated. This proposal will identify which fracture patients are at highest risk of re-fracture and premature death (b) identify whether osteoporosis treatment decreases

\$343,682	this risk and (c) increase osteoporosis awareness and treatment uptake by general practitioners with an integrated fracture risk prediction tool.
Professor Helena Teede	Generating and translating evidence into practice in womens health and beyond
Monash University	Obesity is increasing with major reproductive and metabolic health impacts for women and the next generation. This fellowship focuses on prevention of obesity and optimal diagnosis and management of obesity related reproductive and metabolic conditions in
\$494,733	women including before and during pregnancy. Translation is vital to deliver health benefits from research. Here Prof Teede will generate new evidence and translate this into practice in women's health and beyond to deliver tangible impact.
Professor Peter Cameron	Optimising Emergency and Trauma Systems through evidence based pathways
Monash University	Developing systems for emergency and trauma care based on strong evidence and robust data systems is crucial to the acute health sector. Through an extensive, well recognised collaboration of research groups at The Alfred, Monash and the National
\$412,277	Trauma Research Institute, we aim to undertake world leading systems development both locally and globally, focusing on prehospital, emergency and trauma clinical care pathways significantly reducing mortality and improving functional outcomes.
Associate Professor Andrew Wei	Translational Research Program to Advance Clinical Outcomes in Acute Myeloid Leukaemia
Monash University	Five-year survival in acute myeloid leukaemia (AML) is only 27%, placing it amongst the worst-ranked cancers for clinical outcome. Improved patient outcomes will be
\$412,419	achieved through implementation of a Translational Research Program to support novel agent drug testing, early-phase and randomised clinical trials and a national clinical registry to audit outcomes. New insights into leukaemic stem cell function and
Associate Professor	mechanisms of drug resistance will inform the design of future clinical trials. Mild traumatic brain injury and the risk of long-term neurodegenerative and
Paul McCrory	neurobehavioural disease
Florey Institute of Neuroscience and Mental Health	Considerable media attention surrounds the potential for long-term problems in individuals with high exposure to head impacts such as seen in sporting, civilian and/or military contexts. This study examines the long-term effects of mild traumatic brain injury (mTBI) and helps close the current knowledge gap of the impact of this disorder
\$577,188	on individuals. There are no long term trials to answer the critical question of whether mild TBI causes long term problems in the brain.
Professor Alexander Thompson	Elimination of HCV as a Public Health Threat
University of Melbourne	This Practitioner Fellowship will support studies that will contribute directly to the efforts to eliminate HCV infection from Australia. The research program aims to reduce transmission of HCV infection by evaluating the best models of care for i) engaging and treating high risk individuals with HCV infection, including people who inject drugs
\$481,155	and prisoners, ii) preventing reinfection with HCV, and iii) re-treatment of individuals who fail treatment due to drug resistance.
Professor Bala Venkatesh	Sepsis Outcomes Research
The George Institute for Global Health	Sepsis is a major cause of hospitalization and ICU admission in Australia population corresponding to more than 15,700 new cases each year. Every year more than 3,000 people die from sepsis in Australia which is greater than the annual national road toll and breast, prostate or colorectal cancer. The research outlined in this proposal to study
\$274,946	the effect of steroids and vitamin D to improve patient's recovery from sepsis and also understand the genetic basis behind their ability to survive sepsis.
Assistant Professor Lianne Schmaal	Neuroimaging in mental health: the quest for clinically useful biomarkers
University of Melbourne	To ultimately improve treatment of mental illness, this research program aims to detect robust and reliable neuroimaging markers that are associated with affective disorders by pooling data from many samples across the world. Moreover, this research aims to
\$431,000	develop alternative biological-based classifications of mental illness in young people, and evaluate their clinical value by examining their predictive value for treatment response and disease course.

Associate Professor	Cognitive Phenotyping and Personalised Treatment for Methamphetamine Addiction
Antonio Verdejo- Garcia	Prevention and treatment of addiction to stimulants such as methamphetamine is
Monash University	imperative for community health and safety. This fellowship will enable me to apply my expertise in impulsivity and addiction to identify people at risk of increasing
\$476,728	methamphetamine use and to develop and evaluate cognitive training therapies that will empower people with methamphetamine related problems to control their drug use. Outcomes include a risk identification and triage tool and three novel therapies.
Doctor David	Significance of low-level mosaicism to intellectual disability in paediatric disorders
Godler	My vision for the next 4 years is to improve outcomes for children and their families
Murdoch Childrens Research Institute	with inherited disorders associated with intellectual disability (ID) and autism through earlier diagnosis and intervention. This is of great importance with annual costs of ID
\$476,728	close \$14.72 billion to the Australian health system, and missed or delayed diagnoses being a significant problem, as ID is found in 1.7% of births, where a specific cause is currently identified in less than half.
Associate Professor Christopher Davey	Examining new treatments and developing new treatment biomarkers for youth with severe depression
University of Melbourne	Antidepressant medications and psychotherapy have been the mainstays of depression treatment in young people, but given their modest effectiveness, there is a pressing need
\$333,709	for new treatment strategies. During this fellowship I aim to examine better treatments for depression, and develop better predictors about who is likely to benefit from them.
Doctor Donna	Improving outcomes in low back pain: Targeting specific therapies to patient subgroups
Urquhart	improving curve in 10% curve pulm 1 anguing opposition unitage to pull-out one groups
Monash University	Low back pain is a major health problem worldwide. There is a lack of effective treatments and a "one size fits all" approach to treatment is being used. This innovative research program aims to change the way back pain is treated, by identifying specific
\$429,055	types of back pain, determining the effectiveness of treatments for these types of back pain, and translating a targeted approach to management into clinical practice to improve the health of individuals with back pain.
Doctor Louise	Improving upper limb function in Hereditary Cerebellar Ataxia
Corben	r · · · · · · · · · · · · · · · · · · ·
	Friedreich ataxia (FRDA) causes in-coordination and muscle weakness which may
Murdoch Childrens Research Institute	result in the affected person being unable to walk or use their arms effectively. Incoordination is a result of destruction of nerves in the spine and the area of the brain that controls movement (cerebellum). This study will assess the use of brain stimulation to
\$431,000	improve coordination and function in people with FRDA. The results of this study may also result in treatments for similar inherited cerebellar ataxias.
Associate Professor Steven Tong	Optimising interventions for Staphylococcus aureus and skin infections
Steven rong	Staphylococcal and streptococcal infections are major causes of illness and death,
University of	particularly in Indigenous Australians. These include invasive bloodstream infections
Melbourne	and skin infections that lead to chronic kidney and heart disease. I will conduct clinical
\$333,709	trials to optimise the management of staphylococcal bloodstream infections using novel trial methods, and use genomics and mathematical modelling to understand and reduce the burden of skin infections in Indigenous communities.
Doctor Jill Newby	Improving internet-delivered psychological therapies for depression and anxiety
University of New	Depression and anxiety affect 3 million Australians. While effective psychological
South Wales	treatments exist, even the best only help 50% recover, and relapse is common. My
\$431,000	research aims to improve the treatment of adult depression and anxiety, through developing more effective, efficient and accessible internet-delivered psychological
D + G 11	therapies and identifying the conditions that promote optimal long-term outcomes.
Doctor Saurabh Kumar	Role of Non-Invasive Imaging using Speckle Tracking Echocardiography in the Identification and Treatment of Patients At Risk of Arrhythmias and Consequent Sudden Cardiac Arrest
Western Sydney	
Local Health District	Every year, 15,000 Australians die from sudden cardiac arrest. Identifying individuals at risk is a major challenge. We will investigate whether a heart ultrasound technique

\$431,000	called speckle tracking allows clinicians to rapidly identify changes in heart muscle that are associated with cardiac arrest. If found to be positive, the technique may be broadly applied to large populations, identifying at risk individuals, potentially rescuing them before cardiac arrest occurs.
Doctor Dawn Aitken	Improving musculoskeletal pain by matching the right treatment with the right patient
University of Tasmania	Musculoskeletal pain is common, disabling, and costly in Australia. Current treatment options are poor. This program of research uses clinical trials to investigate new therapy
\$431,000	options for osteoarthritis and chronic low back pain. These studies aim to provide new effective treatment options for patients that can improve pain, slow joint damage and decrease the overall burden of musculoskeletal disease.
Doctor Dominik	Sleep apnea and atrial fibrillation
Linz	
	Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder.
The University of	Obstructive sleep apnea (OSA), is four times more common among patients with AF
Adelaide	than without. OSA has been associated with a greater recurrence rate of AF after
\$431,000	initially successful treatment of AF and treatment of OSA reduces recurrence of AF. To identify the underlying mechanisms, we aim to determine effects of OSA on atrial electrical activation and to characterize sleep apnea in AF patients in a more precise way.
Associate Professor Meg Jardine	Understanding and optimising the delivery of chronic disease care for better cardiovascular outcomes
University of New	The proposed research program will undertake research that utilises existing clinical
South Wales	information and structures. This information will provide evidence in a cost effective manner. A particular project will examine current treatment delivered to people with
\$476,728	chronic disease. A second project will embed a study of the optimum level of sodium
	exposure in dialysis within routine clinical practice. The outcome will be a cost-efficient study that will potentially lead to improve outcomes.